Adds to Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products

增加了公司广泛的高级伤口护理（“AWC”）产品组合

MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions.

2023年9月26日（GLOBE NEWSWIRE）-MiMedx Group，Inc。（纳斯达克股票代码：MDXG）（“MiMedx”或“公司”）今天宣布推出EPIEFFECT™, 该公司最新增加的AWC解决方案组合。

EPIEFFECT expands the Company’s core AWC offering for clinicians treating acute and chronic, hard-to-heal wounds such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), among other common conditions. EPIEFFECT offers a thick, tri-layer configuration that is suitable for securing the graft in place with sutures.

EPIEFFECT扩展了该公司的核心AWC，为临床医生提供治疗急性和慢性，难以愈合的伤口，如糖尿病足溃疡（“DFU”）和静脉性腿部溃疡（“VLU”）等常见疾病。EPIEFFECT提供厚的三层配置，适合用缝合线将移植物固定到位。

In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds..

此外，其产品属性和操作特性使其成为深部或隧道伤口的首选治疗选择。。

“We are delighted to introduce another innovation in the Wound & Surgical marketplace,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “EPIEFFECT provides a thick, tri-layer option to our customers, including those in the private physician office setting. Our approach is to provide the most clinically-effective and evidence-based products possible in the markets we serve, that are designed to meet specific customer demand and use cases.

MIMEDX首席执行官Joseph H.Capper说：“我们很高兴在伤口和外科市场引入另一项创新。”。“EPIEFFECT为我们的客户提供了一个厚而三层的选择，包括私人医生办公室的客户。我们的方法是在我们服务的市场中提供最具临床效果和循证产品，旨在满足特定客户需求和用例。

We believe EPIEFFECT effectively addresses the need for a robust allograft solution, available in an assortment of sizes, to address complex wounds in-office before hospital-based intervention may be required.”.

我们相信EPIEFFECT有效地解决了对各种尺寸的强大同种异体移植物解决方案的需求，以便在可能需要基于医院的干预之前解决办公室中的复杂伤口问题“。

Dr. Christopher Gill, D.P.M., M.S., a podiatrist at the McLaren Bay Region Wound Care Center in Bay City, Michigan added, “I am very excited to incorporate EPIEFFECT into my wound care treatment strategy. As a longtime advocate of EPIFIX, I have seen firsthand how MIMEDX’s product portfolio can be ideally suited for a variety of patients in need of an allograft solution.

密歇根州湾市麦克拉伦湾地区伤口护理中心足病医生克里斯托弗·吉尔博士补充说：“我非常高兴将EPIEFFECT纳入我的伤口护理治疗策略。作为EPIFIX的长期倡导者，我第一手看到了MIMEDX的产品组合如何非常适合需要同种异体移植解决方案的各种患者。

Specifically, I appreciate the level of robust scientific and clinical evidence that supports the development of MIMEDX’s product offerings, and with EPIEFFECT, I look forward to having another innovative option for a wide range of wound types.”.

具体而言，我感谢支持MIMEDX产品开发的强大科学和临床证据水平，并感谢EPIEFFECT为各种伤口类型提供另一种创新选择“。

Mr. Capper continued, “As we have been preparing for its launch, customer anticipation for EPIEFFECT is high and we look forward to seeing how this product can help patients with chronic and hard-to-heal wounds.”

Capper先生继续说：“当我们一直在准备推出时，客户对EPIEFFECT的期望很高，我们期待着看看该产品如何帮助患有慢性和难以愈合伤口的患者。”

About EPIEFFECT

外延

EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes, while also retaining the intermediate layer. EPIEFFECT is intended for use as a barrier, to provide a protective environment in acute and chronic wounds; the tissue provides a biocompatible human extracellular matrix (“ECM”) and contains more than 300 regulatory proteins.

EPIEFFECT是由羊膜和绒毛膜组成的冻干的基于人胎盘的同种异体移植物，同时还保留中间层。EPIEFFECT旨在用作屏障，为急性和慢性伤口提供保护环境；该组织提供了生物相容的人细胞外基质（“ECM”），并包含300多种调节蛋白。

EPIEFFECT is available in a variety of size options ranging from 6 cm2 to 49 cm2. Additionally, like EPIFIX® and EPICORD®, EPIEFFECT is listed on the Medicare Part B Average Sales Price File, effective October 1, 2023. To learn more, please visit https://www.mimedx.com/epieffect/..

EPIEFFECT有多种尺寸选项，范围从6 cm2到49 cm2。此外，与EPIFIX®和EPICORD®一样，EPIEFFECT在Medicare B部分平均销售价格文件中列出，自2023年10月1日起生效。要了解更多信息，请访问https://www.mimedx.com/epieffect/..

About MIMEDX

关于MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.

MIMEDX是专注于帮助人类治愈的先驱和领导者。凭借十多年的帮助临床医生管理慢性和其他难以愈合的伤口，MIMEDX致力于为伤口护理，烧伤和医疗保健外科领域的应用提供领先的产品组合。该公司的愿景是通过不懈的创新来恢复生活质量，成为全球领先的治疗解决方案提供商。

For additional information, please visit www.mimedx.com..

有关更多信息，请访问www.mimedx.com。。

Contact:

联系方式：

Matt Notarianni

马特·诺蒂亚尼

Investor Relations

投资者关系

470-304-7291

470-304-7291

mnotarianni@mimedx.com

mnotarianni@mimedx.com